 Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious diseaseoncology pipeline of six therapeutics. including three in clinical trials including HB-101 for CMV Phase 2, HB-201 for HPV16 Cancer Phase 12, and HB-201-202 for HPV16 Cancer Phase 1. 